BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33374332)

  • 1.
    Barry KH; Mohanty K; Erickson PA; Wang D; Shi J; Rose G; Cellini A; Clark K; Ambulos N; Yin J; Yan L; Poulin M; Meyer A; Zhang Y; Bentzen SM; Burke A; Hussain A; Berndt SI
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenome-Wide Association Study of Prostate Cancer in African Americans Identifies DNA Methylation Biomarkers for Aggressive Disease.
    Xu Y; Tsai CW; Chang WS; Han Y; Huang M; Pettaway CA; Bau DT; Gu J
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant Hypermethylation-Mediated Suppression of PYCARD Is Extremely Frequent in Prostate Cancer with Gleason Score ≥ 7.
    Miyauchi T; Takahashi M; Mitsuzuka K; Saiki Y; Okubo T; Vertino PM; Goto A; Arai Y; Horii A; Fukushige S
    Dis Markers; 2021; 2021():8858905. PubMed ID: 33628338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
    Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
    Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
    Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.
    Wu Y; Davison J; Qu X; Morrissey C; Storer B; Brown L; Vessella R; Nelson P; Fang M
    Epigenetics; 2016 Apr; 11(4):247-58. PubMed ID: 26890304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
    Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk.
    Barry KH; Moore LE; Sampson JN; Koutros S; Yan L; Meyer A; Reddy M; Oler AJ; Cook MB; Fraumeni JF; Yeager M; Amundadottir LT; Berndt SI
    Br J Cancer; 2017 May; 116(11):1470-1479. PubMed ID: 28463958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
    Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
    Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copy number alterations are associated with metastatic-lethal progression in prostate cancer.
    Wang X; Grasso CS; Jordahl KM; Kolb S; Nyame YA; Wright JL; Ostrander EA; Troyer DA; Lance R; Feng Z; Dai JY; Stanford JL
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):494-506. PubMed ID: 32071439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy.
    Jentzmik F; Krause H; Reichelt U; Schrader AJ; Schrader M; Baumunk D; Cash H; Miller K; Schostak M
    World J Urol; 2012 Aug; 30(4):541-6. PubMed ID: 21947551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation levels at chromosome 8q24 in peripheral blood are associated with 8q24 cancer susceptibility loci.
    Barry KH; Moore LE; Sampson J; Yan L; Meyer A; Oler AJ; Chung CC; Wang Z; Yeager M; Amundadottir L; Berndt SI
    Cancer Prev Res (Phila); 2014 Dec; 7(12):1282-92. PubMed ID: 25315430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.
    Kron K; Trudel D; Pethe V; Briollais L; Fleshner N; van der Kwast T; Bapat B
    Clin Cancer Res; 2013 Jul; 19(13):3450-61. PubMed ID: 23549870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential DNA Methylation in Prostate Tumors from Puerto Rican Men.
    Ruiz-Deya G; Matta J; Encarnación-Medina J; Ortiz-Sanchéz C; Dutil J; Putney R; Berglund A; Dhillon J; Kim Y; Park JY
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33450964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.
    Zhao S; Geybels MS; Leonardson A; Rubicz R; Kolb S; Yan Q; Klotzle B; Bibikova M; Hurtado-Coll A; Troyer D; Lance R; Lin DW; Wright JL; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Clin Cancer Res; 2017 Jan; 23(1):311-319. PubMed ID: 27358489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score.
    De Luca S; Passera R; Bollito E; Milillo A; Scarpa RM; Papotti M; Coda R; Randone DF
    Anticancer Res; 2013 Oct; 33(10):4657-62. PubMed ID: 24123045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revised Gleason grading system is a better predictor of indolent prostate cancer at the time of diagnosis: retrospective clinical-pathological study on matched biopsy and radical prostatectomy specimens.
    Giunchi F; Brunocilla E; Borghesi M; Rizzi S; Ricci MS; Romagnoli D; Martorana G; Schiavina R; Fiorentino M
    Clin Genitourin Cancer; 2014 Oct; 12(5):325-9. PubMed ID: 24583160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
    Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
    Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.